Medicine and Dentistry
Breast Cancer
100%
Oncology
44%
Cyclophosphamide
44%
Metastatic Breast Cancer
25%
Adjuvant Chemotherapy
23%
Treatment Response
22%
Positron Emission Tomography-Computed Tomography
22%
Whole Body MRI
22%
Diffusion MRI
22%
Fluorine-18
22%
Malignant Neoplasm
22%
Epirubicin
22%
Combination Therapy
22%
Fluorouracil
22%
Fluorodeoxyglucose F 18
22%
Ovary Function
22%
Phase III Trials
22%
Docetaxel
22%
Methotrexate
22%
Doxorubicin
22%
Hormone Determination
16%
Medical Oncology
13%
Overall Survival
13%
Progressive Disease
12%
Fluorodeoxyglucose
12%
Hormone Therapy
11%
Follitropin
11%
Estrogen Receptor
11%
Patient Population
11%
Clinical Trial
11%
Anthracycline
11%
Goserelin
11%
Progression Free Survival
9%
Magnetic Resonance Imaging
9%
Diseases
7%
Recurrence Free Survival
6%
Amenorrhea
5%
Primary Ovarian Insufficiency
5%
Gonadorelin Derivative
5%
Premenopause
5%
Odds Ratio
5%
Tamoxifen
5%
Diagnostic Accuracy
5%
Pharmacology, Toxicology and Pharmaceutical Science
Breast Cancer
93%
Chemotherapy
51%
Cyclophosphamide
44%
Phase III Trials
22%
Lapatinib
22%
Combination Therapy
22%
Epirubicin
22%
Docetaxel
22%
Methotrexate
22%
Fluorouracil
22%
Doxorubicin
22%
Estrogen Receptor
13%
Overall Survival
13%
Neoplasm
10%
Biological Marker
10%
Epidermal Growth Factor Receptor
8%
Diseases
7%
Recurrence Free Survival
6%
Follitropin
6%
Goserelin
6%
Nursing and Health Professions
Breast Cancer
55%
Adjuvant Chemotherapy
23%
Fluorouracil
22%
Methotrexate
22%
Cyclophosphamide
22%
Epirubicin
22%
Anthracycline
11%
Patient Population
11%
Estrogen Receptor
11%
Randomization
11%
Live Birth
8%
Recurrence Free Survival
6%
